tirzepatide surpass-5 five - SURPASS-CVOT trialtirzepatide SURPASS-5 was a 40-week randomized, double-blind trial Tirzepatide SURPASS-5: A Deep Dive into Efficacy and Safety in Type 2 Diabetes Management

SURPASS-CVOT trialtirzepatide The SURPASS-5 clinical trial represents a crucial element in understanding the efficacy and safety profile of tirzepatide, a novel dual GIP/GLP-1 receptor agonist, when utilized as an add-on therapy for individuals with type 2 diabetes. This phase 3, 40-week, double-blind, placebo-controlled study specifically investigated the drug's impact on glycemic control and body weight in adults already receiving insulin glargine. The comprehensive findings from tirzepatide surpass-5 have been instrumental in shaping the treatment paradigm for this chronic condition.

SURPASS-5 evaluated tirzepatide at three distinct doses: 5 mg, 10 mg, and 15 mg, administered once weekly via subcutaneous injection.A Study of Tirzepatide (LY3298176) Versus Placebo in ... Participants were randomized to receive one of these tirzepatide doses or a placebo, in addition to their titrated insulin glargine regimen. Some participants also continued on their existing metformin therapy, reflecting real-world clinical practice.SURPASS-5 Data: Tirzepatide Plus Insulin Glargine ... The primary objective was to assess the drug's ability to improve glycemic control, measured by the reduction in hemoglobin A1c (HbA1c) levels, compared to placebo.

The results from the SURPASS-5 trial demonstrated a significant and dose-dependent reduction in HbA1c for all tirzepatide treatment groupsEfficacy and Safety of Tirzepatide in Type 2 Diabetes. Patients receiving tirzepatide experienced considerably greater reductions in HbA1c compared to those on placebo, indicating superior glycemic control. Furthermore, the study highlighted that tirzepatide not only improved blood sugar levels but also led to substantial and sustained reductions in body weight. This dual action is a key differentiator for tirzepatide, offering a comprehensive approach to managing type 2 diabetes and its associated comorbidities.

Beyond the primary endpoints, SURPASS-5 also provided valuable data on secondary outcomes and patient-reported experiences. The analysis revealed that tirzepatide achieved the composite outcome of glycemic control and weight loss with a notable absence of severe hypoglycemia佛历2564年6月29日—InSURPASS-5, all threetirzepatidedoses delivered superior A1C reductions and weight reductions compared to placebo both added to titrated .... This finding is particularly significant as maintaining glycemic control without increasing the risk of hypoglycemia is a paramount goal in diabetes management. The SURPASS-5 was a 40-week randomized, double-blind trial that meticulously collected safety data, revealing that tirzepatide was generally well-tolerated across the studied doses. Common adverse events were primarily gastrointestinal in nature, such as nausea and diarrhea, which were mostly mild to moderate in severity and often transient.

The SURPASS-5 study is part of a larger clinical program, the SURPASS trials, which have collectively assessed the efficacy and safety of tirzepatide in a broad T2D population across various treatment settings. Data from SURPASS-CN-INS, another trial within the program, further supports the utility of tirzepatide as an add-on therapy. The consistent positive findings across the five global Phase 3 trials from the SURPASS program have solidified tirzepatide's position as a potent therapeutic option717-P: Glycemic Control with Tirzepatide in People with Type .... The tirzepatide surpass-5 results, in particular, underscore its effectiveness when tirzepatide is added to insulin glargine作者：L Guo·2025·被引用次数：2—In the phase 3SURPASS-5trial, patients with type 2 diabetes inadequately controlled with basal insulin who received once-weeklytirzepatide.... This combination approach has shown that tirzepatide helped improve glycemic control and facilitated significant improvements in both HbA1c and body weight outcomes.

In summary, the SURPASS-5 trial has been pivotal in establishing the robust efficacy and favorable safety profile of tirzepatide when used as an adjunct to basal insulin therapy in individuals with type 2 diabetes.Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, is. Effective and Safe When Added to Basal Insulin for. Treatment of Type 2 Diabetes (SURPASS-5). Dominik Dahl1 ... The trial's design and execution, characterized as SURPASS-5 was a phase 3, 40-week, double-blind, placebo-controlled study, ensured the reliability of its findings作者：D Dahl·2022·被引用次数：638—TheSURPASS-5study evaluated the efficacy and safety of 3 doses oftirzepatide(5 mg, 10 mg, and 15 mg) compared with placebo as an .... The demonstrated ability of tirzepatide to significantly lower HbA1c and reduce body weight, coupled with a manageable safety profile, positions it as a valuable advancement in the ongoing effort to effectively manage type 2 diabetes.作者：N Rasouli·2023·被引用次数：1—The Phase 3SURPASS-1 to -5studies showed safety and efficacy of TZP in improvement of glycemic management and body weight (BW) reduction in adults with T2D.